Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis

Genome‐wide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the International Clopidogrel Pharmacogenomics Consortium (ICPC)

(2020) Shefali Setia Verma et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis

(2019) Zhong-Guo Fan et al.   Drug Design Development and Therapy

Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting

(2019) Jesse Martin et al.   GENETICS IN MEDICINE

Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI

(2019) Jun Liu et al.   THROMBOSIS RESEARCH

A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI

(2019) Daniel M.F. Claassens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients

(2019) Joshua P Lewis et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

(2018) Larisa H. Cavallari et al.   JACC-Cardiovascular Interventions

Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials

(2018) Babikir Kheiri et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study

(2018) Hyung Joon Joo et al.   Scientific Reports

Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy

(2018) Lisa Gross et al.   THROMBOSIS AND HAEMOSTASIS

CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials

(2018) Babikir Kheiri et al.   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS

CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis

(2017) Ziwei Xi et al.   PLATELETS

Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients

(2017) Fei-Yan Xiao et al.   Scientific Reports

Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic AttackClinical Perspective

(2016) Yuesong Pan et al.   CIRCULATION

Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2

(2016) Xingyang Yi et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study

(2016) Hisao Ogawa et al.   Journal of Cardiology

Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population

(2016) De-Liang Shen et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease

(2016) Qiang Niu et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Towards precision medicine

(2016) Euan A. Ashley   NATURE REVIEWS GENETICS

Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention

(2016) A. Komosa et al.   THROMBOSIS RESEARCH

Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands

(2016) B. A. L. M. Deiman et al.   Netherlands Heart Journal

Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes

(2016) Peng Dong et al.   MEDICAL SCIENCE MONITOR

A New Initiative on Precision Medicine

(2015) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel: A Meta-Analysis

(2014) M. J. Sorich et al.   Circulation-Cardiovascular Genetics

Clinical implications of drug-drug interactions with P2Y12receptor inhibitors

(2014) J. M. Siller-Matula et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention

(2014) Jolanta M. Siller-Matula et al.   PLoS One

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

(2013) S A Scott et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile of the Oral Antiplatelet Agent Ticagrelor

(2012) Renli Teng   CLINICAL PHARMACOKINETICS

Standardized Bleeding Definitions for Cardiovascular Clinical Trials

(2011) Roxana Mehran et al.   CIRCULATION

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

(2010) Jessica L. Mega et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data

(2010) M. J. SORICH et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

(2010) Lars Wallentin et al.   LANCET